Skip to Content
Merck
  • Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Talanta (2012-01-31)
Catarina L Silva, Mário Passos, José S Câmara
ABSTRACT

A sensitive assay to identify volatile organic metabolites (VOMs) as biomarkers that can accurately diagnose the onset of breast cancer using non-invasively collected clinical specimens is ideal for early detection. Therefore the aim of this study was to establish the urinary metabolomic profile of breast cancer patients and healthy individuals (control group) and to explore the VOMs as potential biomarkers in breast cancer diagnosis at early stage. Solid-phase microextraction (SPME) using CAR/PDMS sorbent combined with gas chromatography-mass spectrometry was applied to obtain metabolomic information patterns of 26 breast cancer patients and 21 healthy individuals (controls). A total of seventy-nine VOMs, belonging to distinct chemical classes, were detected and identified in control and breast cancer groups. Ketones and sulfur compounds were the chemical classes with highest contribution for both groups. Results showed that excretion values of 6 VOMs among the total of 79 detected were found to be statistically different (p<0.05). A significant increase in the peak area of (-)-4-carene, 3-heptanone, 1,2,4-trimethylbenzene, 2-methoxythiophene and phenol, in VOMs of cancer patients relatively to controls was observed. Statistically significant lower abundances of dimethyl disulfide were found in cancer patients. Bioanalytical data were submitted to multivariate statistics [principal component analysis (PCA)], in order to visualize clusters of cases and to detect the VOMs that are able to differentiate cancer patients from healthy individuals. Very good discrimination within breast cancer and control groups was achieved. Nevertheless, a deep study using a larger number of patients must be carried out to confirm the results.

MATERIALS
Product Number
Brand
Product Description

Supelco
Acetone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Acetone, ≥99.5%, ACS reagent
Supelco
L-Menthol, Pharmaceutical Secondary Standard; Certified Reference Material
(−)-Menthol, primary reference standard
Supelco
Guaiacol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Octanoic acid, ≥99%
Sigma-Aldrich
Guaiacol, oxidation indicator
Sigma-Aldrich
Decanoic acid, ≥98.0%
Sigma-Aldrich
(1R,2S,5R)-(−)-Menthol, ReagentPlus®, 99%
Sigma-Aldrich
p-Cymene, ≥97%, FG
Sigma-Aldrich
Acetic acid, natural, ≥99.5%, FG
Sigma-Aldrich
4-Methyl-2-pentanone, ≥99%, FCC
Sigma-Aldrich
Decanoic acid, ≥99.5%, FCC, FG
Sigma-Aldrich
Acetone, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Hexanoic acid, purum, ≥98.0% (GC)
Supelco
Acetic acid, analytical standard
Supelco
p-Cymene, analytical standard
Supelco
4-Methyl-2-pentanone, analytical standard
Supelco
Decanoic acid, analytical standard
Sigma-Aldrich
(−)-Menthol, puriss., meets analytical specification of Ph. Eur., BP, USP, 98.0-102.0%
Sigma-Aldrich
Isovaleraldehyde, 97%
Sigma-Aldrich
Octanoic acid, ≥98%, FG
Sigma-Aldrich
1-Octanol, ≥98%, FCC, FG
Sigma-Aldrich
Octanoic acid, natural, ≥98%, FG
Sigma-Aldrich
1-Octanol, natural, ≥98%, FCC
Sigma-Aldrich
Acetic acid, for luminescence, BioUltra, ≥99.5% (GC)
Supelco
Mettler-Toledo Calibration substance ME 18555, Benzoic acid, analytical standard, (for the calibration of the melting point system), traceable to primary standards (LGC)
Sigma-Aldrich
p-Cymene, 99%
Sigma-Aldrich
Acetone, ≥99%, meets FCC analytical specifications
Sigma-Aldrich
Decanoic acid, natural, ≥98%, FCC, FG